The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis
Polyzois Makras, Socrates E. Papapoulos, Stergios A. Pοlyzos, Natasha M. Appelman‐Dijkstra, Athanasios D. Anastasilakis
Topics & Concepts
DenosumabDiscontinuationBone remodelingBone mineralMedicineOsteoporosisPostmenopausal womenBone Density Conservation AgentsInternal medicineBisphosphonateEndocrinologyOncologyUrologyBone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases